Sertraline for Panic Disorder

What research says

EveryOption research summary

The current ZOLOFT label reports three double-blind, placebo-controlled studies in adult outpatients with panic disorder. This bounded assessment does not compare every option or determine personal suitability.

See sourceDailyMed sertraline (Zoloft) label · checked Oct 16, 2026

Source for the opening statement

Relationship: supports bounded conclusion

This statement’s scope

Population: source-defined population

Published supporting passage

The effectiveness of ZOLOFT in the treatment of PD was demonstrated in three double‑blind, placebo‑controlled studies (Studies PD-1, PD-2, and PD‑3) of adult outpatients who had a primary diagnosis of PD (DSM‑III‑R), with or without agoraphobia.

All published source details

Population: source-defined population
Completeness: Not assessed
Need: Panic Disorder

Source collection coverage: country:US
Source pointer: /sections/2

Open published source

EveryOption’s published assessment

Research suggests benefit in this exact scope

Published Sep 20, 2026 · revision 1

Find care

Choose a place to see published offerings. A listing does not confirm current availability.

Choose a place Compare published Treatments for this Need

Why this Treatment appears for this Need

Why this Treatment appears in the Need landscape, separate from the research conclusion.

See relationship sourceDailyMed sertraline (Zoloft) label · checked Oct 16, 2026

Relationship: label-reported clinical studies for the Need